U.S. review of Biogen Alzheimer's drug could have been handl

U.S. review of Biogen Alzheimer's drug could have been handled better -FDA chief


By Syndicated Content
By Carl O’Donnell and Trisha Roy
(Reuters) -The U.S. Food and Drug Administration could potentially have done more to avoid the current controversies around its accelerated approval of Biogen Inc’s Alzheimer’s drug, Aduhelm, FDA acting Commissioner Janet Woodcock said during a Wednesday summit hosted by Stat.
The FDA last week called for an independent federal probe into its representatives’ interactions with Biogen ahead of the regulator’s approval of Aduhelm last month.
“The accelerated approval was based on very solid grounds,” Woodcock said during Stat’s Breakthrough Science Summit.
However, she said, “It is possible the process could have been handled in a way that would have decreased the amount of controversy involved.”

Related Keywords

New York , United States , Bengaluru , Karnataka , India , American , Leslie Adler , Trisha Roy , Janet Woodcock , Carl Odonnell , Biogen Inc Alzheimer , Twitter , Drug Administration , Reuters , Carlo Donnell , Biogen Inc , Commissioner Janet Woodcock , Breakthrough Science , Marguerita Choy , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பெங்களூரு , கர்நாடகா , இந்தியா , அமெரிக்கன் , திரிஷா ராய் , ஜேனட் மரக்கட்டை , கார்ல் ஓடொன்னேழில் , பயோஜென் இன்க் முதுமறதி , ட்விட்டர் , ராய்ட்டர்ஸ் , கார்லோ டோனெல் , பயோஜென் இன்க் , ஆணையர் ஜேனட் மரக்கட்டை , திருப்புமுனை அறிவியல் , மார்குரிட்டா சோய் ,

© 2025 Vimarsana